Management of pouch related symptoms in patients who underwent ileal pouch anal anastomosis surgery for adenomatous polyposis.
Adenomatous polyposis syndromes
Familial adenomatous polyposis
Ileal pouch anal anastomosis
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
16 Nov 2021
16 Nov 2021
Historique:
received:
12
06
2021
revised:
23
07
2021
accepted:
23
09
2021
entrez:
8
12
2021
pubmed:
9
12
2021
medline:
9
12
2021
Statut:
ppublish
Résumé
Adenomatous polyposis syndromes (APS) patients with ileal pouch anal anastomosis (IPAA) suffer frequent symptoms with scarce signs of inflammation, distinct from ulcerative colitis patients. While the management of pouchitis in ulcerative colitis patients is well established, data regarding response to treatment modalities targeting pouch-related disorders in APS patient population is scarce. To assess clinical, endoscopic and histologic response to various treatment modalities employed in the therapy of pouch related disorders. APS patients who underwent IPAA between 1987-2019 were followed every 6-12 mo and pouch-related symptoms were recorded at every visit. Lower endoscopy was performed annually, recording features of the pouch, cuff and terminal ileum. A dedicated gastrointestinal pathologist reviewed biopsies for signs and severity of inflammation. At current study, files were retrospectively reviewed for initiation and response to various treatment modalities between 2015-2019. Therapies included dietary modifications, probiotics, loperamide, antibiotics, bismuth subsalicylate, mebeverine hydrochloride, 5-aminosalicylic acid compounds and topical rectal steroids. Symptoms and endoscopic and histologic signs of inflammation before and after treatment were assessed. Pouchitis disease activity index (PDAI) and its subscores was calculated. Change of variables before and after therapy was assessed using Wilcoxon signed rank test for continuous variables and using McNemar's test for categorical variables. Thirty-three APS patients after IPAA were identified. Before treatment, 16 patients (48.4%) suffered from abdominal pain and 3 (9.1%) from bloody stools. Mean number of daily bowel movement was 10.3. Only 4 patients (12.1%) had a PDAI ≥ 7. Mean baseline PDAI was 2.5 ± 2.3. Overall, intervention was associated with symptomatic relief, mainly decreasing abdominal pain (from 48.4% to 27.2% of patients, APS patients benefit from dietary modifications and probiotics that improve their pouch-related symptoms but respond minimally to anti-inflammatory and antibiotic treatments. These results suggest a functional rather than inflammatory disorder.
Sections du résumé
BACKGROUND
BACKGROUND
Adenomatous polyposis syndromes (APS) patients with ileal pouch anal anastomosis (IPAA) suffer frequent symptoms with scarce signs of inflammation, distinct from ulcerative colitis patients. While the management of pouchitis in ulcerative colitis patients is well established, data regarding response to treatment modalities targeting pouch-related disorders in APS patient population is scarce.
AIM
OBJECTIVE
To assess clinical, endoscopic and histologic response to various treatment modalities employed in the therapy of pouch related disorders.
METHODS
METHODS
APS patients who underwent IPAA between 1987-2019 were followed every 6-12 mo and pouch-related symptoms were recorded at every visit. Lower endoscopy was performed annually, recording features of the pouch, cuff and terminal ileum. A dedicated gastrointestinal pathologist reviewed biopsies for signs and severity of inflammation. At current study, files were retrospectively reviewed for initiation and response to various treatment modalities between 2015-2019. Therapies included dietary modifications, probiotics, loperamide, antibiotics, bismuth subsalicylate, mebeverine hydrochloride, 5-aminosalicylic acid compounds and topical rectal steroids. Symptoms and endoscopic and histologic signs of inflammation before and after treatment were assessed. Pouchitis disease activity index (PDAI) and its subscores was calculated. Change of variables before and after therapy was assessed using Wilcoxon signed rank test for continuous variables and using McNemar's test for categorical variables.
RESULTS
RESULTS
Thirty-three APS patients after IPAA were identified. Before treatment, 16 patients (48.4%) suffered from abdominal pain and 3 (9.1%) from bloody stools. Mean number of daily bowel movement was 10.3. Only 4 patients (12.1%) had a PDAI ≥ 7. Mean baseline PDAI was 2.5 ± 2.3. Overall, intervention was associated with symptomatic relief, mainly decreasing abdominal pain (from 48.4% to 27.2% of patients,
CONCLUSION
CONCLUSIONS
APS patients benefit from dietary modifications and probiotics that improve their pouch-related symptoms but respond minimally to anti-inflammatory and antibiotic treatments. These results suggest a functional rather than inflammatory disorder.
Identifiants
pubmed: 34877323
doi: 10.12998/wjcc.v9.i32.9847
pmc: PMC8610899
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9847-9856Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: None of conflict of interest.
Références
Aliment Pharmacol Ther. 1997 Dec;11(6):1041-6
pubmed: 9663827
Arch Surg. 2005 Mar;140(3):300-10
pubmed: 15781797
Dis Colon Rectum. 2006 Sep;49(9):1293-306
pubmed: 16830218
World J Gastroenterol. 2010 Feb 7;16(5):547-53
pubmed: 20128021
Dis Colon Rectum. 2007 Apr;50(4):498-508
pubmed: 17279300
Gastroenterol Hepatol (N Y). 2017 Feb;13(2 Suppl 1):1-16
pubmed: 28729815
Dis Colon Rectum. 2009 Aug;52(8):1481-6
pubmed: 19617764
Clin Gastroenterol Hepatol. 2016 Sep;14(9):1296-301
pubmed: 27085760
Am J Gastroenterol. 2002 Apr;97(4):972-7
pubmed: 12003434
Clin Transl Gastroenterol. 2020 Oct;11(10):e00245
pubmed: 33031194
Aliment Pharmacol Ther. 2020 Oct;52(8):1323-1340
pubmed: 32955120
Inflamm Bowel Dis. 2011 Apr;17(4):994-1002
pubmed: 20684016
Aliment Pharmacol Ther. 2002 Jan;16(1):27-34
pubmed: 11856075
Gastroenterology. 2003 May;124(6):1636-50
pubmed: 12761722
Inflamm Bowel Dis. 2018 Apr 23;24(5):989-996
pubmed: 29688472
Inflamm Bowel Dis. 2007 Dec;13(12):1522-8
pubmed: 17828776
World J Gastroenterol. 2015 Aug 7;21(29):8739-52
pubmed: 26269664
J Clin Pharm Ther. 2011 Jun;36(3):275-82
pubmed: 21545610
N Engl J Med. 1989 Jan 26;320(4):257
pubmed: 2911318